CAIX si/shRNA inhibits GBM growth and enhances anti-VEGF therapy, while the CAIX/XII small molecule inhibitor SLC-0111 in combination with TMZ prevents GSC enrichment and increases survival 82, 107, 108. Here, VEGFA is linked to glioblastoma.